Strategic Partnership to Establish Cambridge Isotope Laboratories, Pvt. Ltd. in Hyderabad’s Genome Valley, Enhancing Global Production and Supply of Isotopically Enriched Chemical Solutions for Pharmaceutical and Electronics Industries
TEWKSBURY, MA AND HYDERABAD, INDIA / ACCESS Newswire / October 27, 2025 / Cambridge Isotope Laboratories, Inc. (CIL), and Chemtatva Chiral Solutions, Pvt. Ltd. (CCS), a leading provider of chiral and specialty chemical solutions, announce the execution of a signed Memorandum of Understanding to establish Cambridge Isotope Laboratories, Pvt. Ltd. in Hyderabad, India. This initiative marks a milestone in the expansion of CIL’s global footprint and further enhances capabilities in the development and production of deuterated reagents and other isotopically enriched products. This partnership will enhance global supply chain strength and real-time support for customers in Asia and enable multi-site production for global customers focused on business continuity. The forthcoming entity, Cambridge Isotope Laboratories, Pvt. Ltd., is expected to be officially established in Q4 2025, subject to customary diligence and closing considerations. Operations for the newly formed entity will be initiated at existing CCS facilities, with a net new facility slated for groundbreaking in 2026. The new facility will be located in India’s Genome Valley, a burgeoning 2,000-acre life sciences cluster located in suburban Hyderabad.
Cliff Caldwell, CEO at CIL noted, “We are excited to partner with CCS to combine our chemistry expertise and pursue scale-up technologies to further support pharmaceutical and industrial applications. This initiative reflects our commitment to supporting global research and development efforts in scientific fields as well as supporting the growing commercial needs for deuterium labeled and specialty chemical products in the pharmaceutical and electronics industries.”
Vishal Rajput, CEO of CCS said, “The collaboration and newly formed entity will leverage CCS’s strong infrastructure and deep technical capabilities in India, while integrating CIL’s world-class standards in isotope chemistry, quality systems, global logistics and go-to market capabilities.” Mr. Rajput will lead the newly formed entity as general manager of Cambridge Isotope Laboratories, Pvt. Ltd. The legacy CCS business will remain intact, with the collective intent to expand access to high quality, isotopically labeled and unlabeled compounds for customers worldwide, with an emphasis on downstream synthetic compounds and a commitment to industry-specific product quality requirements.
All CIL, Eurisotop and CCS branded and manufactured materials remain available to Indian and worldwide customers through existing channels. Further details regarding the launch and operational scope of Cambridge Isotope Labs Pvt. Ltd. will be shared in the coming months.
About Cambridge Isotope Laboratories, Inc. CIL, a subsidiary of Otsuka Pharmaceutical in Japan, is the largest manufacturer and global supplier in the world of stable isotopes and stable isotope‑labeled compounds. Trusted by industrial and academic collaborators since 1980, CIL’s products are used in research, diagnostics, environmental, pharmaceutical, medical diagnostic, OLED, and industrial applications. CIL’s operations include two facilities in the Boston, MA, area; a large isotope‑enrichment production plant in Xenia, OH; CIL China; CIL Canada; ABX in Dresden, Germany (specializing in radioisotopic‑labeled compounds for cancer diagnosis and treatment); and Eurisotop in Saclay, France.
About Chemtatva Chiral Solutions, Pvt. Ltd. CCS is a Hyderabad-based company founded in 2021, specializing in chiral chemistry, process development, and custom synthesis for pharmaceutical and chemical industries. CCS is a trusted global partner in life sciences, delivering innovative chemistry solutions that solve complex challenges and accelerate scientific progress.
SHELTON, CT / ACCESS Newswire / October 27, 2025 / NanoViricides, Inc. (NYSE American: NNVC ) (the “Company”), a clinical stage leader developing revolutionary broad-spectrum antiviral drugs that the virus cannot escape, announced that it will be presenting on Monday, October 27th, at 03:00pm at the PODD 2025 Conference in Boston, MA.
Event Information:
Event
NanoViricides Presentation at the PODD 2025, Boston, MA
Track
5A
Date
Monday, October 27, 2025
Time
03:00 pm
Location
St. George, ABC, at Westin Copley Hotel, Boston, MA
Anil R. Diwan, PhD, President and Executive Chairman of the Company will provide an update on the Company, its Drug Pipeline and Platform Technologies available for licensing.
NanoViricides’ Current Antiviral Drugs Pipeline
NanoViricides lead clinical stage drug candidate NV-387 is rapidly moving into Phase II for the treatment of MPox in the Democratic Republic of Congo.
A separate Phase II clinical trial for the evaluation of NV-387 as a first line therapy of any respiratory viral infection (NV-387 for the treatment of Viral Acute or Severe Acute respiratory Infections, Viral ARI/SARI, is being planned. Success in this clinical trial would enable NV-387 to become the first ever antiviral drug that can be prescribed by a physician based on symptoms, as an emperic therapy for respiratory viral infections, without having to test for which virus is causing the disease.
The revolutionary broad antiviral spectrum of NV-387 is reminiscent of the dawn of antibiotics to combat bacterial infections.
NV-387 was found to be highly effective against the “tripledemic” respiratory viruses, namely RSV, Influenza A, and Coronaviruses, in respective lethal animal models of lung infection. NV-387 was found to be substantially superior to existing drugs, and even resulted in complete cure in the RSV animal study. These studies prompted evaluation of NV-387 as a first line therapy of respiratory viral infections.
There is no treatment approved for RSV.
NV-387 has shown excellent effectiveness in lethal lung infection animal models relevant for Smallpox and MPox viruses.
There is no treatment approved for MPox; tecovirimat (TPOXX) has failed clinical trials, and no results are available from the brincidofovir (TEMBEXA) clinical trial “MOSA”.
Additionally, NV-387 has shown excellent effectiveness against Measles virus lethal lung infection in a humanized (hCD150+ knock-in) mouse model.
There is no treatment approved for Measles. Cases of Measles have been rapidly rising in the developing world including USA, Canada, UK and European countries. Measles is an important health threat because the disease can lead to “immune amnesia”, wiping out pre-developed immunity against other diseases, because it attacks the immune system itself.
The nanoviricides™ platform technology is yielding novel antiviral drug candidates against a number of challenging viral targets at a rapid pace.
Our most advanced candidate, NV-387, is an ultra-broad-spectrum antiviral with potential activity against most respiratory human pathogenic viruses – and more, because it emulates the attachment receptor family of sulfated proteoglycans that over 90% of human viruses utilize.
Moreover, NV-387 is designed to shape-shift upon binding to the virus particle, in the process disrupting the virus particle and making it incapable of infection, as a complete chemical nanomachine that destroys the virus.
Viruses are unlikely to escape NV-387 because no matter how much a virus evolves, it continues to utilize and require binding to sulfated proteoglycans – the very characteristic that NV-387 emulates. This solves the long-standing problem of antiviral medicines, that viruses escape them. Vaccines, antibodies and small chemical drugs are readily escaped by viruses as the viruses evolve in the field. This has been repeatedly observed during the recent COVID-19 pandemic, as well as in the course of most of the other viral epidemics including Influenza and HIV/AIDS.
Continued redevelopment or “updating” of vaccines necessitated by the viral escape or drift has recurrently cost billions of dollars every year for Influenza as well as COVID. NV-387 promises to make such costly endeavors unnecessary, once this drug is approved by regulatory bodies.
NV-387 is rapidly moving towards Phase II Safety, Tolerability and Efficacy Evaluation for the Treatment of MPOX disease, in response to the continuing Public Health Emergency of International Concern in WHO African Region. We already have received preliminary approval of the clinical protocol and the study and now we are working diligently to finish and submit the clinical trial application.
The overall market size of NV-387 indications is estimated to be well in excess of $10 billion.
In addition, the Company has developed a clinical-ready pan-herpesvirus drug candidate, NV-HHV-1 that has shown activity against HSV-1, HSV-2 and VZV, and is expected to have activity against CMV, HHV-6, and HHV-8 as well.
The Company has also developed an anti-HIV drug candidate, NV-HIV-1, that has shown strong efficacy in SCID-hu-Thy-Liv animal model of HIV infection. NV-HHV-1 mimics the landing site on cellular CD4 that is required for all HIV viruses to cause cellular infection. Thus, HIV, despite constant changes, will be unable to escape NV-HHV-1.
NanoViricide Platform Enables Drug Rescue, Oral Drug Delivery, and Zip-Code Specific Delivery
Oral drug delivery of small chemicals, peptides (such as the GLP-a obesity drugs), and proteins is feasible by encapsulation of the guest drug into the nanoviricide polymeric micelle. The encapsulation protects the guest from metabolism thereby enabling effective drug delivery.
Encapsulation of a difficult or failed drug within the nanoviricide polymeric micelle can enable rescue of the drug candidate turning it into a clinically viable drug candidate, saving hundreds of millions of dollars of development work.
Going another step further, the nanoviricide platform technology can be customized to enable zip-code-like specific delivery of encapsulated drugs to specific tissues (e.g. non-liver targeted delivery),, cells (e.g. cancer-cell specific delivery sparing normal cells), bacteria, or viruses (e.g. NV-HHV-1, NV-HIV-1) in a fully synthetic chemistry based, scalable technology stack.
Pharma, biotech and drug delivery industries will gather at the 15th annual PODD event to assess delivery needs, explore partnership opportunities, and stay at the forefront of innovative drug delivery technologies. This includes small molecules, biologics, combination products, connected devices, cell and gene delivery and more.
PODD provides partnering opportunities through organized networking for new, emerging and established collaborations.
NanoViricides, Inc. (the “Company”) ( www.nanoviricides.com ) is a clinical stage company that is creating special purpose nanomaterials for antiviral therapy. The Company’s novel nanoviricide™ class of drug candidates and the nanoviricide™ technology are based on intellectual property, technology and proprietary know-how of TheraCour Pharma, Inc. The Company has a Memorandum of Understanding with TheraCour for the development of drugs based on these technologies for all antiviral infections. The MoU does not include cancer and similar diseases that may have viral origin but require different kinds of treatments.
The Company has obtained broad, exclusive, sub-licensable, field licenses to drugs developed in several licensed fields from TheraCour Pharma, Inc. The Company’s business model is based on licensing technology from TheraCour Pharma Inc. for specific application verticals of specific viruses, as established at its foundation in 2005.
Our lead drug candidate is NV-387, a broad-spectrum antiviral drug that we plan to develop as a treatment of RSV, COVID, Long COVID, Influenza, and other respiratory viral infections, as well as MPOX/Smallpox infections. Our other advanced drug candidate is NV-HHV-1 for the treatment of Shingles. The Company cannot project an exact date for filing an IND for any of its drugs because of dependence on a number of external collaborators and consultants. The Company is currently focused on advancing NV-387 into Phase II human clinical trials.
NV-CoV-2 (API NV-387) is our nanoviricide drug candidate for COVID-19 that does not encapsulate remdesivir. NV-CoV-2-R is our other drug candidate for COVID-19 that is made up of NV-387 with remdesivir encapsulated within its polymeric micelles. The Company believes that since remdesivir is already US FDA approved, our drug candidate encapsulating remdesivir is likely to be an approvable drug, if safety is comparable. Remdesivir is developed by Gilead. The Company has developed both of its own drug candidates NV-CoV-2 and NV-CoV-2-R independently.
The Company is also developing drugs against a number of viral diseases including oral and genital Herpes, viral diseases of the eye including EKC and herpes keratitis, H1N1 swine flu, H5N1 bird flu, seasonal Influenza, HIV, Hepatitis C, Rabies, Dengue fever, and Ebola virus, among others. NanoViricides’ platform technology and programs are based on the TheraCour® nanomedicine technology of TheraCour, which TheraCour licenses from AllExcel. NanoViricides holds a worldwide exclusive perpetual license to this technology for several drugs with specific targeting mechanisms in perpetuity for the treatment of the following human viral diseases: Human Immunodeficiency Virus (HIV/AIDS), Hepatitis B Virus (HBV), Hepatitis C Virus (HCV), Rabies, Herpes Simplex Virus (HSV-1 and HSV-2), Varicella-Zoster Virus (VZV), Influenza and Asian Bird Flu Virus, Dengue viruses, Japanese Encephalitis virus, West Nile Virus, Ebola/Marburg viruses, and certain Coronaviruses. The Company intends to obtain a license for RSV, Poxviruses, and/or Enteroviruses if the initial research is successful. As is customary, the Company must state the risk factor that the path to typical drug development of any pharmaceutical product is extremely lengthy and requires substantial capital. As with any drug development efforts by any company, there can be no assurance at this time that any of the Company’s pharmaceutical candidates would show sufficient effectiveness and safety for human clinical development. Further, there can be no assurance at this time that successful results against coronavirus in our lab will lead to successful clinical trials or a successful pharmaceutical product.
This press release contains forward-looking statements that reflect the Company’s current expectation regarding future events. Actual events could differ materially and substantially from those projected herein and depend on a number of factors. Certain statements in this release, and other written or oral statements made by NanoViricides, Inc. are “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. You should not place undue reliance on forward-looking statements since they involve known and unknown risks, uncertainties and other factors which are, in some cases, beyond the Company’s control and which could, and likely will, materially affect actual results, levels of activity, performance or achievements. The Company assumes no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future. Important factors that could cause actual results to differ materially from the company’s expectations include, but are not limited to, those factors that are disclosed under the heading “Risk Factors” and elsewhere in documents filed by the company from time to time with the United States Securities and Exchange Commission and other regulatory authorities. Although it is not possible to predict or identify all such factors, they may include the following: demonstration and proof of principle in preclinical trials that a nanoviricide is safe and effective; successful development of our product candidates; our ability to seek and obtain regulatory approvals, including with respect to the indications we are seeking; the successful commercialization of our product candidates; and market acceptance of our products.
The phrases “safety”, “effectiveness” and equivalent phrases as used in this press release refer to research findings including clinical trials as the customary research usage and do not indicate evaluation of safety or effectiveness by the US FDA.
FDA refers to US Food and Drug Administration. IND application refers to “Investigational New Drug” application. cGMP refers to current Good Manufacturing Practices. CMC refers to “Chemistry, Manufacture, and Controls”. CHMP refers to the Committee for Medicinal Products for Human Use, which is the European Medicines Agency’s (EMA) committee responsible for human medicines. API stands for “Active Pharmaceutical Ingredient”. WHO is the World Health Organization. R&D refers to Research and Development.
NORTH YORK, ON / ACCESS Newswire / October 27, 2025 / ZTEST Electronics Inc. (“ZTEST” or the “Company“) (CSE:ZTE)(OTCID:ZTSTF) announces fiscal 2025 revenues of $8,319,302, including $2,113,637 in Q4, representing the third consecutive quarter with very modest revenue growth. Revenues for the corresponding periods of 2024 were $9,756,044, inclusive of the record revenues of $2,791,359 in the final quarter.
Financial Highlights
Fiscal Year End
(in thousands of dollars, except per share amounts)
June 2025
June 2024
Revenue
8,319
9,756
Gross Margin
3,457
3,918
Gross Margin as a % of Revenue
41.6
40.2
Net Income
1,089
1,753
Net Income per share (basic)
0.030
0.058
EBITDA
1,837
2,599
Operating Cash Flow
1,657
2,280
Financial Position
As at
(in thousands of dollars)
Jun 30 2025
Jun 30 2024
Cash
4,105
2,776
Working Capital
5,008
3,593
Long-term Debt
56
121
Shareholders’ Equity
5,807
4,497
Financial Highlights
Three months ended
(in thousands of dollars, except per share amounts)
Dec 31 2025
Dec 31 2024
Revenue
2,114
2,791
Gross Margin
872
1,171
Gross Margin as a % of Revenue
41.3
41.9
Net Income
300
546
Net Income per share (basic)
0.008
0.016
EBITDA
494
870
Operating Cash Flow
415
809
Steve Smith, CEO commented, “The EMS market entered a cyclical decline in the second half of fiscal 2024 and the imposition and threat of tariffs added to the market malaise. As a contract assembler our business levels tend to trail general market swings leading to a strong finish to fiscal 2024 followed by generally smaller orders in fiscal 2025. We realized modest revenue growth in each of the final three quarters of 2025 and are very encouraged by the positive signs that began in the latter part of the third quarter of 2025, both domestic and export, suggesting that market confidence is returning. We believe that our extensive efforts to nurture existing customer relationships, and foster new customer relationships, is starting to pay off.”
The Company also wishes to announce that Steve Smith, Dean Tyliakos, David Barnett and William R. Johnstone were re-elected to the Board of Directors and Kreston GTA LLP, Chartered Professional Accountants, were re-appointed as auditors of the Company for the ensuing year at the annual meeting of shareholders held on Friday October 24, 2025.
About ZTEST Electronics Inc.
ZTEST Electronics Inc., through its wholly owned subsidiary Permatech Electronics Corporation (“Permatech”), offers Electronic Manufacturing Services (EMS) to a wide range of customers. Permatech’s offering includes Printed Circuit Board (PCB) Assembly, Materials Management and Testing services. Permatech operates from an ISO 9001:2015 certified facility in North York, Ontario, Canada. Permatech is a contract assembler of complex circuit boards, serving customers in the Medical, Power, Computer, Telecommunications, Wireless, Industrial, Trucking, Wearables and Consumer Electronics markets. It specializes in servicing customers who are looking for high yield and require high quality and rapid-turnaround on low and mid-volume production of high complexity products.
For more information contact: Steve Smith, CEO (604) 837-3751 email: steves@ztest.com
Neither the Canadian Securities Exchange nor its Market Regulator (as that term is defined in the policies of the CSE) accepts responsibility for the adequacy or accuracy of this release.
FORWARD LOOKING STATEMENTS: This press release contains forward looking statements, which relate to future events or future performance and reflect management’s current expectations and assumptions. Such forward looking statements reflect management’s current beliefs and are based on assumptions made by and information currently available to the Company. Investors are cautioned that these forward-looking statements are neither promises nor guarantees and are subject to risks and uncertainties that may cause future results to differ materially from those expected. These forward looking statements are made as of the date hereof and, except as required under applicable securities legislation, the Company does not assume any obligation to update or revise them to reflect new events or circumstances. All of the forward-looking statements made in this press release are qualified by these cautionary statements and by those made in our filings with SEDAR+ in Canada (available at www.sedarplus.com).
Oct. 26, 2025 / PRZen / ALTMUNSTER, Austria — Uniform refrigerant distribution and effective condensate drainage have long been among the main engineering challenges in microchannel evaporator design. While Kaltra’s previous coil generations successfully solved these aspects individually, certain demanding conditions — such as low-load operation, frosting, or use in reversible heat-pump systems — continued to push design limits.
Driven by the goal of achieving flawless performance under all operating scenarios, Kaltra’s R&D team has taken the technology a step further. The result is a new, revolutionary generation of microchannel evaporator coils that ensure stable operation under the most challenging thermal conditions and enable full reversibility as condenser coils in heat-pump applications.
The breakthrough comes with a configuration that places the microchannel tubes horizontally — a layout traditionally avoided in evaporator designs due to poor condensate drainage. Kaltra’s engineers overcame this limitation by replacing individual folded fin stripes with vertical louver-fin plates with leading edges. These edges, which maintain a higher surface temperature than the flat tube, slow the cooling process and direct the formed condensate efficiently downward, ensuring complete drainage and improving frost management and de-icing performance.
With the new vertical louvered-fin plates, condensate drainage and coil behavior under frosting conditions closely match that of conventional finned-tube coils, as the fin geometry of Kaltra’s new evaporator coils closely resembles that of traditional designs — while retaining all the advantages of microchannel technology.
The new horizontal-tube arrangement additionally allows for multi-pass refrigerant circuitry, delivering higher overall heat-transfer performance and superior efficiency in reversible (condenser) operation.
Another key innovation lies in the manifold design. The manifolds feature a special internal geometry with intermediate orifice plates, which promote turbulent mixing of the refrigerant’s gas and liquid fractions. This improves uniformity of refrigerant across all microchannel tubes, ensuring consistent thermal performance and preventing the formation of superheated regions.
The circuit geometry has also been optimized by adjusting the number of tubes in each refrigerant pass, improving overall coil performance for both evaporator and condenser modes. With this design, Kaltra achieves an optimal balance between evaporator and condenser performance, ensuring high efficiency and stable operation in reversible systems.
This latest coil generation was developed with a clear focus on heat pump applications, one of the fastest-growing segments in HVAC technology. Reliable reversibility, consistent drainage under frosting conditions, and minimized pressure drop make these coils an ideal choice for modern heat pump systems that must maintain performance across a wide range of ambient conditions. Extensive laboratory and field testing have confirmed the coils’ outstanding performance under repeated frosting and defrosting cycles.
The organic skincare and holistic wellness brand has gained significant consumer recognition due to its innovative formulations and commitment to quality. With a focus on natural ingredients and sustainable practices quickly establishing a strong presence in the market.
Oct. 25, 2025 / PRZen / MURPHY, N.C. — Wild Hermit Wellness is quickly establishing itself as a beacon of hope in the skincare industry, championing affordable holistic wellness and the embrace of natural beauty. Since its launch two months ago, the brand has garnered global attention for its innovative approach to skincare and hair care, centering on goat milk and eco-friendly, natural ingredients. Wild Hermit Wellness offers a carefully curated range of organic products designed for eco-conscious consumers who value both efficacy and ethical standards.
The inception of Wild Hermit Wellness by founders Samantha and T. Craig McManus was inspired by the increasing awareness among consumers about the ingredients in their personal care products. Recognizing a gap in the market for products that are both effective and environmentally responsible, the founders, alongside a dedicated team, have crafted a line of skin-nourishing and eco-friendly solutions. Their commitment to sustainability and reverence for Earth’s natural resources drives their mission.
Each product is made from organic ingredients—free from sulfates, parabens, and phthalates—ensuring gentleness for both skin and planet. The use of natural retinol and chemical-free anti-aging alternatives distinguishes Wild Hermit Wellness as a luxurious yet ethical choice. Their globally lauded bestseller, the Organic Goat Milk & Okra Peptide Shampoo and Conditioner Bundle, exemplifies their innovative spirit, designed to rejuvenate scalp, roots, and strands.
Wild Hermit’s success story is not just about products but about transformation—both for its customers and the wider beauty industry. It heralds a future where sustainable, natural beauty is not merely a trend but a lasting commitment. This ethos is encapsulated in their motto: “Sustainable, Eco-Friendly, Always Organic.”
Samantha and Craig McManus state, “At Wild Hermit Wellness, we believe in the harmony between nature and self-care. Our dedication to sustainability and the earth’s bounty is woven into every product we create.”
As the holiday season approaches, Wild Hermit is delighted to announce a special sale on their Etsy store and website, featuring their new Lineage Line, among other cherished collections. Additionally, they offer custom exotic woodworking gifts and handmade pottery, perfect for holiday gifting.
Nestled in the Appalachian Mountains, Wild Hermit was born from a profound connection to nature and a desire to create from the heart. Their bestselling books and holistic wellness programs further reflect their commitment to fostering a community centered around wellness.
For more information about Wild Hermit Wellness and their offerings, visit their website at https://www.wildhermit.com, explore their Etsy store, or delve into their educational resources at https://www.semcmanus.com.
About Wild Hermit Wellness:
Wild Hermit is dedicated to crafting naturally derived beauty and wellness products. Prioritizing sustainability and the interconnectedness of life, they create with excellence and innovation to enhance well-being through organic care.
Vancouver, WA October 26, 2025 –(PR.com)– ETC Mining, a global cloud computing platform focused on clean-energy operations, today announced the launch of a new mobile app designed to provide users with a more convenient way to participate in cloud mining. Through this mobile tool, users can manage mining contracts anytime and anywhere, monitor computing performance in real time, and track revenue.
Meeting Global Demand for Green Cloud Mining
The launch of this mobile app follows growing global interest in blockchain and sustainable mining models. As major digital assets such as XRP, BTC, and ETH continue to attract attention as part of the broader digital-asset economy, ETC Mining states that its mobile solution aims to offer a transparent and environmentally conscious approach to cloud mining.
Technology-Driven Simplified Experience
Founded in 2019 and headquartered in the UK, ETC Mining reports that it operates data centers in regions including Eastern Europe, North America, Central Asia, and Australia. The platform provides computing power support through distributed infrastructure and artificial-intelligence scheduling designed to optimize resources for BTC, ETH, LTC, ETC, and other networks.
An ETC Mining spokesperson said:
“Our goal is to make cloud mining easier to manage and more transparent. The mobile app provides users with accessible tools and improved control over their mining activities.”
Security and Sustainability
ETC Mining’s security framework includes SSL encryption and distributed server redundancy to help protect data and transactions. The company also reports ongoing investment in renewable-energy infrastructure, such as solar and wind power, to support the sustainability of its cloud-mining operations.
Southport, CT October 26, 2025 –(PR.com)– Last night, October 23, Family Law Firm Conlon Amendola, in partnership with MoCACT, hosted a vibrant event at their elegant Southport offices to celebrate the 49th year of the Heida Hermanns International Music Competition.
The event drew renowned attorneys, art collectors, and VIPs, who savored delicacies from a “jaw droppingly beautiful” grazing table as well as a selection of passed hors d’oeuvres by A&S Westport Catering & Events.
“The Heida” competition, a prestigious platform for pianists aged 18-30 worldwide, was highlighted with remarks by “Heida” champion Kristin Foster, a member of MoCACT Board of Directors and Performing Arts Advisory Committee, as well as the presence of longtime “Heida” benefactors, Suzanne and Norman Sorensen.
“My wife Suzanne and I have supported MoCACT and the Heida Hermanns competition for ten years, and it’s been a true privilege,” said Sorensen. “MoCACT has done commendable work in attracting young, aspiring artists.” In his remarks, Mr. Sorensen emphasized the need for increased funding to sustain opportunities for talented musicians who lack resources to showcase their skills.
Dr. Joan Miller of Capital Prep Harbor School shared heartfelt insights, noting the competition’s impact on inner-city youth by exposing them to transformative cultural experiences. “On the bus ride home after the performance, the children’s faces lit up as they discussed the pianists’ hand movements and the music’s emotional impact,” she remarked. “Some of our children have never left Bridgeport, and giving them the opportunity to see what’s possible was wonderful.” Dr. Miller concluded, “I’d love to do it again. I hope the partnership will continue for years to come.”
The evening underscored the vital role of local businesses in supporting arts and culture. Family Law attorneys Jacquelyn Conlon and Bonnie Amendola, hosts of the event, summed up the sentiment: “We believe it’s important to support MoCA and ‘The Heida’ to keep creativity alive, challenge our perspectives, create opportunities for those in need, and ensure all artists have the freedom to keep moving culture forward.”
The event was a resounding success, shining a spotlight on the importance of community-driven cultural initiatives.
Seattle, WA October 26, 2025 –(PR.com)– MSP Miner, a technology company focused on sustainable blockchain infrastructure, has announced the launch of its next-generation cloud mining platform. Founded in 2018 and headquartered in the United Kingdom, MSP Miner operates global data centers powered by renewable energy sources. The platform aims to make cryptocurrency mining accessible to users worldwide—requiring only a smartphone or computer, without the need for specialized hardware or technical expertise.
Making Mining More Accessible
As the cryptocurrency market evolves, Ethereum (ETH), Dogecoin (DOGE), and Ripple (XRP) continue to hold strong positions among mainstream digital assets. At the same time, energy-efficient cloud mining has emerged as a sustainable and lower-barrier method for users to participate in blockchain validation.
Unlike traditional mining, cloud mining allows participants to remotely lease computing power instead of purchasing and maintaining costly hardware. Users can monitor mining activity through MSP Miner’s online dashboard and manage contracts conveniently from their mobile devices.
Security, Efficiency, and Sustainability
MSP Miner emphasizes transparency, environmental responsibility, and system security. The company states that its facilities use renewable energy—including solar, wind, and hydropower—to reduce carbon emissions and support sustainable blockchain operations.
MSP Miner states that the key features of its platform include:
1. Security and Stability: MSP Miner utilizes McAfee® and Cloudflare® security technologies, combined with cold-storage digital wallets, to help safeguard assets and data.
2. Green Infrastructure: Operations are powered entirely by renewable energy sources for a reduced environmental footprint.
3. User Transparency: The platform provides accessible information on data center operations and mining performance metrics.
4. Smart Operations: Automated management tools allow users to track contract activity and performance metrics in real time.
5. Multi-Currency Support: Users can select mining contracts linked to various digital assets, including BTC, ETH, DOGE, SOL, XRP, USDC, LTC, and USDT.
6. Referral Program: MSP Miner offers optional referral incentives for users who introduce new participants to the platform.
To begin, users can register through the official MSP Miner website and explore available contract options. Each plan is tailored to different budgets and time frames, offering flexibility for individuals interested in participating in remote mining operations.
After registration, users can monitor mining activity and review results through the platform’s dashboard. MSP Miner provides customer support and educational resources to help users understand how cloud mining works and the risks associated with cryptocurrency markets.
About MSP Miner
Established in 2018, MSP Miner focuses on providing technology solutions for cloud-based digital asset mining. Its mission is to promote environmentally friendly mining practices and make blockchain participation accessible to a wider audience.
Denver, CO October 25, 2025 –(PR.com)– Global financial institutions are increasingly exploring the use of digital assets as collateral within institutional lending structures – a sign of growing interest in blockchain-based finance across traditional banking.
According to research by Fleet Asset Management Group, this trend reflects the gradual recognition of digital assets as components of broader financial markets. Fleet notes that the adoption of blockchain infrastructure by established institutions signals a shift toward greater integration between digital and traditional finance.
Fleet Asset Management’s View
“It is not just a regulatory milestone when major banks consider digital assets for collateral purposes — it represents a broader shift in how global markets may view blockchain-based value,” stated an analyst from Fleet’s research division.
Fleet believes that digital assets are gradually evolving from speculative instruments to structured financial tools with potential applications in cross-border financing, asset management, and risk hedging.
Fleet Mining: An AI-Driven Cloud Mining Platform
In this rapidly changing digital economy, investors continue to seek income models that are reliable, transparent, and sustainable. Fleet Asset Management’s cloud mining program aims to address this need.
As a global provider of intelligent cloud mining services, Fleet Mining employs an AI hashrate scheduling engine designed to optimize on-chain efficiency and power allocation.
Key features include:
– AI Algorithm Optimization: Periodic adjustment of hashrate allocation based on network difficulty, energy cost, and price volatility.
– Daily Settlements: Earnings calculated in USDT or BTC every 24 hours, available for withdrawal or reinvestment.
– Flexible Plan Durations: Options from 2 to 60 days, adaptable to different budgets and preferences.
– Transparency and Security: Operations across North America, Northern Europe, and Central Asia are managed through smart contracts available for public verification.
Fleet Mining states that its goal is to make AI-driven hashrate allocation accessible globally, positioning cloud mining as an emerging digital asset model.
Getting Started
Users can visit FleetMining.com to create an account, fund it with supported cryptocurrencies such as USDT, BTC, or ETH, and choose from available contract plans to begin mining.
Fleet Asset Management believes that AI-powered cloud mining represents part of a new era of digital finance – one emphasizing transparency and sustainable participation in the cryptocurrency ecosystem.
Denver, CO October 24, 2025 –(PR.com)– The Hong Kong Securities and Futures Commission (SFC) has approved the first Solana spot ETF by China Asset Management (ChinaAMC), with trading set to begin on October 27. This development makes Hong Kong the first major financial center to offer a regulated Solana investment vehicle to institutional investors — putting it a step ahead of the U.S. market.
The announcement sparked strong market enthusiasm. Solana led gains among the top ten cryptocurrencies, rising about 6% intraday from just under $180 to $192. Analysts now estimate a high likelihood of a U.S. Solana ETF approval, reflecting growing institutional confidence.
As the digital asset landscape continues to evolve, the emergence of AI-powered cloud mining is also redefining how participants generate stable, data-driven crypto rewards.
AI Hashrate Scheduling: Advancing Automated Mining Efficiency
Traditional mining typically requires hardware ownership and ongoing maintenance. AI-powered cloud mining automates this process through smart algorithms that analyze on-chain difficulty, energy prices, and real-time market data to allocate computing resources efficiently.
Fleet Mining, one of the companies active in this area, reports that its AI scheduling technology is designed to optimize hashrate use and support energy efficiency in line with global green and ESG goals. The company describes its platform as offering “zero maintenance and instant activation” for users who want simplified participation in mining networks.
Fleet Mining Core Mechanism: AI + Hashrate Yield Cycle
– Real-Time Scheduling: AI continuously evaluates mining difficulty, energy costs, and network conditions across chains.
– Dynamic Switching: Hashrate is allocated in real time to maximize potential yield.
– Reinvestment Option: Daily mining proceeds in USDT can be withdrawn or reinvested according to user preference.
– Transparency and Security: Fleet Mining states that its global hashrate nodes are located across North America, Northern Europe, and Central Asia, with user earnings processed through verifiable smart contracts.
The company emphasizes that users do not need technical mining experience; operations and tracking are automated through an online dashboard.
2. Select a Plan: Choose among available AI Mining Plans starting from $100.
3. Activate Mining: Once payment is confirmed (via USDT, BTC, or other supported tokens), the AI engine activates within 24 hours. Users may withdraw or reinvest earnings as they accrue.
(Note: Performance figures provided by the company are for illustrative purposes only and are not guarantees of future results.)
Looking Ahead: AI Mining as a Data-Driven Cash Flow Model
Unlike trading or speculative DeFi activities, AI cloud mining focuses on continuous computational output tied to blockchain performance. Industry observers suggest that such models could appeal to users seeking exposure to digital asset operations with automated yield mechanisms.
Fleet Mining believes AI-driven mining will play an increasing role in 2025 as data and automation drive new categories of blockchain-based revenue services.
Conclusion
AI-powered cloud mining continues to evolve from a technical niche into a mainstream, automated service model. Fleet Mining positions itself as part of this movement toward data-based blockchain efficiency and transparent mining operations.
For more information, visit https://FleetMining.com or contact info@fleetmining.com for business inquiries.
